Intraocular pressure lowering by S-allylmercaptocysteine in rabbits.
The purpose of this study was to examine the actions of a garlic-derived compound, S-allylmercaptocysteine (SAMC) on intraocular pressure (IOP) and to determine the possible involvement of sulfhydryl reactivity, sympathetic neuronal activity and atrial natriuretic peptide (ANP) in the IOP response. Topical, unilateral application of SAMC (20, 100, 200 microg) elicited dose-dependent decreases in IOP. The magnitude of the IOP-lowering effect induced by SAMC was between four to six mmHg. The ocular hypotensive responses were unilateral, peaked at one to three hours and lasted from two to four hours. The IOP-lowering effect by SAMC (100 microg) was enhanced modestly by topical, bilateral pretreatment with a reducing agent, tris(2-carboxyethyl) phosphine (100 microg) which itself produced no change in IOP. No alteration of pupil diameter was observed following topical application of either SAMC or tris(2-carboxyethyl) phosphine. Thus, alteration of sulfhydryl reactivity does not seem to be a major mechanism of action for SAMC. SAMC caused no change of basal and electrically stimulated norepinephrine release in rabbit iris-ciliary bodies, ruling out a prejunctional effect on sympathetic nerve activity. However, SAMC increased the ANP levels in aqueous humor by five-fold. It is concluded that the ocular hypotensive response induced by SAMC in rabbits could involve the elevation of ANP levels in aqueous humor.
Department of Pharmacology and Toxicology, Morehouse School of Medicine, Atlanta, Georgia 30310-1495, USA. tc@msm.edu
T C
TC
Chu
P
P
Han
G
G
Han
D E
DE
Potter
D000287:Administration, Topical; D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D002924:Ciliary Body / Q000294:innervation; D003545:Cysteine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007429:Intraocular Pressure / Q000187:drug effects*; D007498:Iris / Q000294:innervation; D009638:Norepinephrine / Q000378:metabolism; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000494:pharmacology; D010720:Phosphines / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects; D011817:Rabbits; D011897:Random Allocation; D013564:Sympathetic Nervous System / Q000378:metabolism
D009320:Atrial Natriuretic Factor; D003545:Cysteine; D009638:Norepinephrine; D009883:Ophthalmic Solutions; D010720:Phosphines; C086300:S-allylmercaptocysteine; C080938:tris(2-carboxyethyl)phosphine